Tumour recurrence is often observed in patients with gastrointestinal (GI) cancers even after a complete resection, indicating that undetectable tumour deposits must be present at the time of surgery. Circulating tumour cells (CTCs) can be released from the primary tumour into the blood stream and colonise distant organs giving rise to metastasis. The FDA-approved CellSearch System (Veridex, Raritan, NJ, USA) is a semi-automated analyser enriching CTCs with ferrofluid nanoparticles coated with anti-EpCAM antibodies. This system has proved to be useful for detecting and analysing CTCs in patients with breast, colorectal or prostate cancer ([@bib9]).

Gastrointestinal cancers are among the most diagnosed of all solid tumours. Although the development of multidisciplinary treatments (such as surgical treatment and chemotherapy) has improved the prognosis of GI cancer, the overall survival of the patients with metastatic or recurrent disease remains dismal. Recently, molecularly targeted therapy has been used in GI cancer, leading to significant improvements in overall survival ([@bib15]; [@bib2]; [@bib3]). Some monoclonal antibodies and kinase inhibitors, targeting EGFR and VEGF/VEGFR, have demonstrated promising efficacy in GI cancer. The ToGA trials revealed the addition of the anti-HER2 agent trastuzumab to chemotherapy in HER2-positive patients significantly improved the overall survival in gastric cancer ([@bib2]). In a clinical setting, the evaluation of HER2 status is restricted to the primary tumour. However, it is reported that assessment of the HER2 status in tissue biopsies carries a significant risk of sampling errors, thereby rendering patients unsuitable for treatment with trastuzumab ([@bib16]). Because the metastasising tumour cells are the primary targets of systemic therapy, it is critical to confirm the expression of HER2 in CTCs. In addition, it is possible that the treatment strategy could be affected by the HER2 status of CTCs.

In the current study, the aims were to elucidate the HER2 status of CTCs in metastatic or recurrent GI cancer at the time of diagnosis by use of the CellSearch System and to assess the correlation of HER2 status between primary tumour and corresponding CTCs.

Materials and methods
=====================

Patients
--------

Between 2008 and 2012, 87 patients with metastatic or recurrent GI cancer (oesophageal, 20; gastric, 34; and colorectal, 33 cases) were prospectively enrolled. All patients were histopathologically positive for GI cancer. Documented informed consent was obtained from all patients, and the study protocol was approved by the local ethics committee.

Clinical samples
----------------

For measurement of CTCs, pre-treatment peripheral blood (PB) samples (7.5 ml) were collected in CellSave tubes at Kumamoto University. All PB samples were immediately transferred to Kanagawa and measured within 48 h. For the patients with distant metastasis at the time of diagnosis, biopsy samples were routinely obtained from the primary tumour through GI endoscopy and made available for the evaluation of HER2 status (oesophageal, 19; gastric, 25; and colorectal, 20 cases). At least three biopsy fragments were assessed in each cases. For the patients with recurrent disease after curative resection, resected specimens of the primary tumour were available for the evaluation of HER2 status (oesophageal, 1; gastric, 9; and colorectal, 13 cases). Normal, negative controls consisted of PB samples that were collected from 10 volunteers lacking malignancies.

CTC measurement
---------------

Peripheral blood samples were enriched with the CellSearch System with ferrofluid nanoparticles coated with anti-EpCAM antibody. The enriched EpCAM+ population was stained with phycoerythrin-conjugated antibodies against CK8, 18 and 19, with allophycocyanin-conjugated antibodies specific for leucocytes (anti-CD45 antibody) and with the nuclear dye 4\', 6-diamino-2-phenylidole (DAPI) for nucleic acid staining. The CK+/DAPI+/CD45− cells were counted as CTCs using a CellTracks Analyzer II (Veridex), a four-colour semi-automated fluorescent microscope ([@bib1]).

Determination of HER2 status of CTCs and primary tumours
--------------------------------------------------------

The HER2 status of CTCs was assessed with the fluorescein-labelled anti-HER2 antibody (CellSearch System Tumour Phenotyping Reagent HER2) as previously reported ([@bib11]). As shown in [Figure 1](#fig1){ref-type="fig"}, HER2 staining of CTCs from GI cancer patients observed in the FITC channel of the CellSearch System was classified as positive or negative in this study as with previous study by [@bib11].

The HER2 status of primary tumours was assessed by immunohistochemical study (HercepTest, Dako, Glostrup, Denmark). The scoring criteria were based on the study by [@bib13] and tumours were classified as 0, 1+, 2+ and 3+.

Statistical analysis
--------------------

For continuous variables, data were expressed as means±standard deviation and compared by the Mann--Whitney test. Association between categorical variables was analysed using a chi-square test and Student\'s *t*-test. Findings were considered significant when the *P*-value was \<0.05. All tests were performed using JMP software (SAS Institute Inc., Cary, NA, USA).

Results
=======

Patient characteristics
-----------------------

A total of 87 patients with metastasis (61 patients) and recurrence (26 patients) and ten healthy volunteers were enrolled in this study. The patient characteristics are summarised in [Table 1](#tbl1){ref-type="table"}. The patterns of metastasis or recurrence included local (8 patients), distant lymph node (10 patients), hematogenous organs such as lung, liver and bone (52 patients) and peritoneal dissemination (17 patients).

Detection of CTCs in GI cancers
-------------------------------

The CellSearch System was used to analyse a total of 87 PB samples from all GI cancers. At least one CTC was detected in 62 samples (71.3%). The mean number of CTCs was 117 (0--4800 cells). No CTCs were detected in any of the samples from healthy volunteers. At least one CTC was detected in 15 of 20 samples (75.0%) in oesophageal cancer, 25 of 34 samples (73.5%) in gastric cancer and 22 of 33 samples (66.6%) in colorectal cancer. The mean number of CTCs was 201 (0--4800 cells), 104 (0--2756 cells) and 18.4 (0--353 cells) in oesophageal, gastric and colorectal cancer, respectively.

HER2 status of CTCs in GI cancers and comparison of HER2 status between CTCs and primary tumours
------------------------------------------------------------------------------------------------

Among the 62 CTC-positive cases, HER2-positive CTCs were detected in 20 (32.3%) cases (6 of 15 oesophageal cancer (40.0%), 7 of 25 gastric cancer (28.0%) and 7 of 22 colorectal cancer (31.8%)). Next, we compared the HER2 status between CTCs and corresponding primary tumours in 62 CTC-positive cases ([Table 2](#tbl2){ref-type="table"}). We found 22 (35.5%) discordant cases (HER2-positive CTCs/HER2-negative in primary tumour 17 of 54 (31.4%), HER2-negative CTCs/HER2-postive in primary tumour 5 of 8 (62.5%). There was no significant correlation of HER2 status between CTCs and primary tumour in all types of cancer.

Discussion
==========

In this study, we revealed the frequency of HER2 expression in CTCs in patients with metastatic or recurrent GI cancer. HER2-positive CTCs were observed in 32.3% of all GI cancer patients. Circulating tumour cells were particularly evident in the patients with hemtogenous metastasis (59.8%). The presence of HER2-positive CTCs has been analysed in breast and bladder cancer ([@bib10]; [@bib4]; [@bib5]; [@bib12]). [@bib11] revealed that HER2 over-expression in CTCs in breast cancer patients was associated with high tumour stage and suggested that determining HER2 status of CTCs could help identify patients who might benefit from trastuzumab-containing regimens in a neoadjuvant setting. Therefore, identification of the HER2 status of CTCs is a logical step because CTCs colonise distant organs, giving rise to metastasis. In fact, a clinical trial testing the use of lapatinib in advanced breast cancer with HER2-negative in primary tumours and HER2-positive or EGFR-positive CTCs was recently completed (clinicaltrials.gov/:NCT00820924). The EORTC group is also planning to launch the 'Treat CTC\' trial. Treat CTC will investigate whether trastuzumab can reduce CTC detection and disease recurrences compared with observation in patients with HER2-negative breast cancer.

There are some limitations concerning about the evaluation of HER2 expression in this study. In our series, we found 22 (35.5%) discordant cases in CTC-positive cases. Among the HER2-negative primary tumours, 31.4% (17 of 54) developed HER2-positive CTCs. Inversely, 62.5% (5 of 8) had HER2-negative CTCs among the HER2-positive primary tumours. No concordance of HER2 status between primary tumour and CTCs was observed in this study as previous several studies ([@bib11]; [@bib5]). There are some possible reasons for discordant HER2 status. First, it is possible that HER2 status of a primary tumour evaluated by biopsy might not reflect the HER2 status of the whole primary tumour. Gastric cancer is well known to have histological heterogeneity, various histological types and differentiation are frequently observed in the same specimen. On the other hand, [@bib14] reported high concordance of HER2 expression between surgically resected specimens and prior biopsy specimens in the HER2-positive group. However, at least three fragments seemed to be required to assess precisely to avoid false-negative results ([@bib14]). Therefore, we assessed at least three biopsy fragments to avoid false-negative result. Second, unlike breast and gastric cancer, the methods for evaluating HER2 status in resected or biopsy specimens have not been established in oesophageal and colorectal cancer. As a result, the frequency of HER2-positive expression in GI cancer varies in several reports ([@bib8]; [@bib6]). Third, it is possible that some cancer patients whose primary tumour was HER2-negative acquired HER2 gene amplification in their CTCs during cancer progression as previously reported ([@bib7]). In this study, only samples obtained at diagnosis before treatment were collected to avoid transition of HER2 status. Furthermore, the discordant of HER2 status seems to be observed in both direction. Interestingly, some cases in HER2-negative CTCs/HER2-positive primary tumours group have close cut-off value of HER2 copy number evaluated by FISH. Therefore, it is critical to evaluate the HER2 status of CTCs because the metastasising tumour cells are the primary target of systemic therapy.

In conclusion, we clarified the frequency of HER2-positive CTCs in metastatic or recurrent GI cancer. The information on the HER2 status of CTC might be helpful for stratification of HER2-directed therapy. More studies are urgently required to test the clinical utility of using CTCs as a liquid biopsy to monitor tumour genotypes and to contribute to personalised treatment strategies in GI cancer.
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![**Representative images of gastric cancer patients with HER2 status in CTCs determined by the FITC-labelled anti-HER2 antibody in the CellSearch System (A) HER2-negative CTC case.** (**B**) HER2-positive CTC case.](bjc2013680f1){#fig1}

###### Patients and characteristics of metastasis and recurrence

                           **OEsophageal cancer (*****N*****=20)**   **Gastric cancer (*****N*****=34)**   **Colorectal cancer (*****N*****=33)**                                                                            
  ----------------------- ----------------------------------------- ------------------------------------- ---------------------------------------- ------ --------------- ------ ------ ------ --------------- ------ ------ ------
  Age                                                                                                                                               0.78                                 0.59                                 0.78
                                        65.8 (55--77)                               65.4                                    64.6                           57.3 (27--83)   56.7   59.3          64.2 (28--81)   65.7   64.5     
  Sex                                                                                                                                               0.17                                 0.01                                 0.62
  Male                                   17 (85.0%)                                  12                                      5                              25 (73.5%)      16     9             14 (42.4%)      10     4       
  Female                                  3 (15.0%)                                   3                                      0                               9 (26.5%)      9      0             19 (57.6%)      12     7       
  Metastatic/recurrent                                                                                                                              0.56                                 0.01                                 0.07
  Metastatic                             14 (70.0%)                                  10                                      4                              25 (73.5%)      16     9             22 (66.7%)      17     5       
  Recurrent                               6 (30.0%)                                   5                                      1                               9 (26.5%)      9      0             11 (33.3%)      5      6       
  Pattern of metastasis                                                                                                                             0.27                                 0.12                                 0.47
  Local                                   1 (5.0%)                                    1                                      0                               1 (2.9%)       1      0              3 (9.1%)       1      2       
  Lymph node                              3 (15.0%)                                   3                                      0                               5 (14.7%)      5      0              2 (6.1%)       1      1       
  Hematogeneous                          16 (80.0%)                                  11                                      5                              17 (50.0%)      10     7             22 (66.6%)      15     7       
  Peritoneal                               0 (0%)                                     0                                      0                              11 (32.4%)      9      2              6 (18.2%)      5      1       

Abbreviation: CTC=circulating tumour cell.

###### Comparison of HER2 status in CTC and corresponding primary tumours

                                                      **HER2 status on primary tumour**                                          
  --------------------------------------------------- ----------------------------------- ------ ------ --- ---- ------ --- ---- ------
  No. of analysed CTC-positive cases                  2                                   13            3   22          3   19    
  CTC-HER2-positive                                   1                                   5      0.75   1   6    0.83   1   6    0.95
  CTC-HER2-negative                                   1                                   8             2   16          2   13    
  Disconcordant rate (%)[a](#t2-fn2){ref-type="fn"}   40.0                                32.0   36.4                            

Abbreviation: CTC=circulating tumour cell.

Discordant results between primary tumour and CTC.
